CTA
JAZZ icon

Carillon Tower Advisers’s Jazz Pharmaceuticals JAZZ Stock Holding History

Carillon Tower Advisers’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-61,925
Closed -$8.83M – 484
2019
Q2 		$8.83M Sell
61,925
-88,825
-59% -$11.9M 0.06% 343
2019
Q1 		$21.6M Sell
150,750
-152,450
-50% -$19.9M 0.15% 231
2018
Q4 		$37.6M Buy
+303,200
New +$45M 0.32% 110

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Carillon Tower Advisers's JAZZ Position: Q3 2019 in Review

Carillon Tower Advisers sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2019, closing a stake of 61,925 shares — an estimated $8.83M sold.

Carillon Tower Advisers first reported a position in JAZZ in Q4 2018 and held it in 3 quarters. The position peaked at $37.6M in Q4 2018. 406 funds tracked by Wall St. Rank hold JAZZ as of Q3 2019.

  • Carillon Tower Advisers reported no remaining Jazz Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Carillon Tower Advisers sold 61,925 Jazz Pharmaceuticals shares in Q3 2019, an estimated $8.83M.
  • Carillon Tower Advisers first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Carillon Tower Advisers's Jazz Pharmaceuticals position peaked at $37.6M in Q4 2018.
  • 406 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2019.

Based on Carillon Tower Advisers's 13F filing for Q3 2019, filed 5 Nov 2019.